Option Care Health (NASDAQ:OPCH – Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided EPS guidance of 0.420-0.450 for the period, compared to the consensus EPS estimate of 0.330. The company issued revenue guidance of $1.3 billion-$1.4 billion, compared to the consensus revenue estimate of $1.3 billion. Option Care Health also updated its FY 2024 guidance to 1.550-1.590 EPS.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Jefferies Financial Group lowered shares of Option Care Health from a “buy” rating to a “hold” rating and cut their target price for the company from $38.00 to $26.00 in a research note on Thursday, October 31st. The Goldman Sachs Group cut Option Care Health from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $38.00 to $27.00 in a research note on Monday, November 4th. Truist Financial decreased their target price on Option Care Health from $41.00 to $34.00 and set a “buy” rating for the company in a research note on Friday, November 1st. UBS Group began coverage on Option Care Health in a report on Thursday, December 5th. They issued a “neutral” rating and a $26.00 price target on the stock. Finally, JMP Securities restated a “market outperform” rating and set a $30.00 price objective (down previously from $31.00) on shares of Option Care Health in a research report on Friday, January 10th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.86.
Check Out Our Latest Research Report on OPCH
Option Care Health Stock Performance
Insiders Place Their Bets
In related news, Director Harry M. Jansen Kraemer, Jr. purchased 43,000 shares of the company’s stock in a transaction on Friday, November 8th. The shares were bought at an average cost of $22.54 per share, for a total transaction of $969,220.00. Following the transaction, the director now owns 326,334 shares of the company’s stock, valued at $7,355,568.36. This represents a 15.18 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.64% of the stock is currently owned by insiders.
Option Care Health Company Profile
Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn’s disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.
See Also
- Five stocks we like better than Option Care Health
- ETF Screener: Uses and Step-by-Step Guide
- AAR Corp Jets Higher on Robust Demand for Aircraft Components
- Dividend Capture Strategy: What You Need to Know
- Everything You Need to Know About Palantir’s Stock Slide
- Insider Trading – What You Need to Know
- Why Nike Is on The Verge of a Massive Comeback Rally
Receive News & Ratings for Option Care Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Option Care Health and related companies with MarketBeat.com's FREE daily email newsletter.